Evidence map›Paper›PMID 40861451›Full record

ArticleFrontiers in immunology2025

Effect of daphnetin combined with tobramycin on

Dingbin Li, Chao Mao, Siyuan Chen, Zhongwei Wang, Weilin Zhang, Zhencong Li, Liangsheng Li, Chaoqin He, Weixiong Guo, Jinsong Wei and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dingbin Li *Department of Spinal Degeneration and Deformity Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China.
Chao Mao *Department of Spinal Degeneration and Deformity Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China.
Siyuan ChenDepartment of Spinal Degeneration and Deformity Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China.
Zhongwei WangDepartment of Spinal Degeneration and Deformity Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China.
Weilin ZhangDepartment of Spinal Degeneration and Deformity Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China.
Zhencong LiDepartment of Spinal Degeneration and Deformity Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China.
Liangsheng LiDepartment of Spinal Degeneration and Deformity Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China.
Chaoqin HeDepartment of Spinal Degeneration and Deformity Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China.
Weixiong GuoDepartment of Spinal Degeneration and Deformity Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China.
Jinsong WeiDepartment of Spinal Degeneration and Deformity Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China.
Qingjun WeiDepartment of Orthopedics, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The aim of this study was to investigate the effectiveness of daphnetin in combination with tobramycin on Method: The study was divided into four groups: control, tobramycin, daphnetin, and tobramycin combined with daphnetin groups. First, a 72-h Results: The results showed that daphnetin had a minimum inhibition concentration (MIC) of 890 µg/mL against the PAO1 strain, while tobramycin had an MIC of 2.75 µg/mL against the same strain. Crystal violet staining and colony counting showed that the biofilm in the group treated with both daphnetin and tobramycin was significantly less than that in the control group (P < 0.05). Scanning electron microscopy further confirmed that the combination of daphnetin and tobramycin had the strongest bactericidal effect. Conclusion: The study indicated that daphnetin may be a promising synergist that enhances the activity of tobramycin against

Indexed as

Anti-Bacterial AgentsBiofilmsPseudomonas aeruginosaPseudomonas InfectionsTobramycinUmbelliferonesAnimalsDisease Models, AnimalDrug Therapy, CombinationMicrobial Sensitivity TestsRabbitsAnti-Bacterial AgentsdaphnetinTobramycinUmbelliferonesbiofilmcombinationdaphnetinPseudomonas aeruginosatobramycin

Identifiers

PMID40861451
PMCPMC12370681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.